Total
0
Shares
G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva - The Market Herald
CEO, Dr Yacov Geva
Source: Finance News Network
  • Telehealth company G Medical Innovations (GMV) has received firm commitments to undertake a $5 million placement
  • To raise the funds, 100 million fully-paid ordinary shares will now be issued to institutional and professional investors at a price of five cents each
  • Shares are expected to issue on or around August 13
  • The company will use the funds to scale-up its Independent Diagnostic Testing Facility (IDTF) operations and increase the manufacturing capabilities of the Prizma device and G Medical Patch
  • The money will also go towards increasing its U.S. sales team
  • G Medical is down 14.3 per cent and shares are currently trading for 5.4 cents each

Telehealth company G Medical Innovations (GMV) has received firm commitments to undertake a $5 million placement.

The company entered a trading halt on Wednesday but did not know how much it would be raising at the time.

To raise the funds, 100 million fully-paid ordinary shares will now be issued to institutional and professional investors at a price of five cents each.

Shares are expected to issue on or around August 13.

G Medical will use the money to scale-up its Independent Diagnostic Testing Facility (IDTF) operations, increase the manufacturing capabilities of the Prizma device and G Medical Patch, and increase its U.S. sales team.

"We now have the financial capacity to fast-track IDTF's growth and fund greater manufacturing volumes for the Prizma and the Patch in anticipation of more purchase orders," CEO, Dr Yacov Geva said.

"We will provide shareholders with an update as these matters progress," Yacov said.

G Medical is down 14.3 per cent and shares are trading for 5.4 cents each at 12:54 pm AEST.


Subscribe


GMV by the numbers
More From The Market Herald
PolyNovo (ASX:PNV) - CEO, Paul Brennan - The Market Herald

" PolyNovo (ASX:PNV) selects Finnish distributor

Healthcare giant PolyNovo (PNV) has selected Innova Medical Oy to distribute its clinical wound treatment in Finland.
Medlab (ASX:MDC)- CEO, Sean Hall - The Market Herald

" Medlab Clinical (ASX:MDC) recieves Australian patent for NanoCelle

Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform.
Proteomics receives CE Mark for kidney disease test

" BARD1 Life Sciences’ (ASX:BD1) ovarian cancer test kit passes muster

BARD1 Life Sciences (BD1) has received positive results from a trial of its improved ovarian cancer test kit.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.